Because Her2/Neu overexpression not only drives breast cancers but also activates the oncogenesis of a variety of other types of human cancers, future studies should determine whether ALA-based modalities are effective for non-breast Her2-overexpressed tumors. Here, ERBB2 is linked to cancer.